The small-cap IT stock, Blue Cloud Softech, has extended its winning streak to the third day, rising by 2.39% to ₹25.64 per share during the intraday session on Thursday, December 11.
Over the past five sessions, the stock has seen a significant surge of nearly 22%. However, in the near term, the share price trend has been negative, with an 11.50% decline in a month and a 56.27% drop in the last year.
Despite the short-term volatility, Blue Cloud Softech has proven to be a multibagger stock, giving returns of 350% over the last five years, making it a wealth-creating machine for its long-term investors.
The company's strong three-day surge is driven by its fundraising plans and AI-focused growth strategy. Blue Cloud Softech has secured in-principle approval from BSE to issue 31,68,00,000 equity shares at ₹23.06 each via preferential allotment.
The company has announced a major global expansion strategy aimed at the $957.30-billion addressable market across 56 Commonwealth countries. The plan focuses on scaling its AI-driven healthcare platforms, including BluBio, BluHealth, and Bioster.
Blue Cloud Softech has also secured a sizeable ₹110.8-crore contract for Data Annotation and AI Training Services from US-based Stratos Forge Inc. The company's order book is strengthening, with a net profit of ₹15 crore in the September quarter, up from ₹11 crore in Q2FY25.
Please note that this story is for educational purposes only, and investors should consult with an investment advisor before making any investment decisions.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram